Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

BCOP > Prostate > Flashcards

Prostate Flashcards

(63 cards)

Start Studying
1
Q

epidemiology -3

A

most common cancer in US

2nd leading cause of cancer death

african am&raquo_space;caucasian both incidence and death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

etiology -2

A

increased exposure to testosterone

genetic (45% of dz if age <55)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

risk factors -3

A

age (median 67),

race (more in blacks, less in asians),

family history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

pathophysiology of sx -3

A

urethra passes through prostrate

THUS sx when hypertrophy

inc freq, inability to start/stop, dyuria, hematuria, nocturia, incomplete emptying, dribbling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Screening -2

A
  1. DRE (25-50% of masses are cancer), PPV 26-35%
  2. PSA, specific to prostate, not to cancer, PPV 40-49%
  3. TRUS (transrectal u/s) indicated after abnormal PSA or DRE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PSA concepts -6

A

> 4.0 abnormal.

between 4-10 could be BPH or CA.

free PSA >25% likely BPH, no bx

free PSA between 15-25%, consider bx

PSA velocity 0.35 per year higher RR death

PSA density: PSA/prostate volume by TRUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Factors affecting PSA -5

A

finasteride, dutasteride (50% dec),

saw palmetto (unpredictable),

androgen receptor blockers (variable, usually inc),

ejaculation (inc),

bx OR DRE (inc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Screening recommendations -3

DO GUIDELINES AGREE?

A

US PSTF lack of evidence that PSA saves lives -> unnecessary testing and tx

European Randomized Study of Prostate CA 20% red in death

US PLCO study no survival advantage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Screening Guidelines -5

A

ACS start annual PSA when age 50,

NCCN, AUA start when 40, if 75y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Prevention - prostate CA prevention trial (PCPT) -6

NOTE: dutasteride no diff in gleason 7-10 CA

A

finasteride vs placebo for 7 yrs;

30% reduction;

nonsig 14% inc in high-grade (gleason 7-10)->thus no FDA approval;

ASCO/AUA guideline consider for asymptomatic with PSA <3.0,

if taking for BPH discuss benefits/risks,

NOTE prevelance dec but morbidity/mortality NOT assessed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Prevention - selenium - SELECT trial

4 arms: selenium, vit e, selenium + vit e, placebo

A

no sig benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Prevention - vitamin e - SELECT trial

A

nonsig (p=0.6) inc risk of prostate CA,

other trials show varying doses of vit e but high dose may be worse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Signs and Symptoms -6

A

asymptomatic early;

advanced -
alterations in micturition,

impotence,

lower extremity edema,

anemia,

wt loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Natural hx -3

A

indolent early,

spreads via local extension (lymphatics, lymph nodes, hematogenously),

met to bone (80%), liver, lung

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Diagnosis -8

A 
PE, 
PSA, 
TRUS, 
serum chem, 
bone scan, 
CT/MRI, 
Bx via TURP, 
99% adenocarcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Staging -3

A

Gleason 1-5 two sections added,

higher the score greater probability of extracapsular spread;
T1: clinically undectable tumor (either palpation or imaging)
T2: confined within prostate
T3: extends through prostate capsule
T4: invades bladder, levator muscles, pelvic wall
NOTE: N1: mets in regional lymph node

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Treatment - localized disease - general concepts

A

depend primarily on stage and grade but also on pt’s age, health, and preferences

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Treatment - localized disease - active surveillance

A

inc anxiety

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Treatment - localized disease - XRT -3

A

equivalent to surgery in outcomes

complications (impotence (30%), rectal/bladder sx).

choice external beam or brachytherapy (not choice for high risk, large or sx dz)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Treatment - localized disease - radical prostatectomy (RP) + pelvic lymph node dissection (PLND) tox. -4

A

complications (early mortality (0.3%),

bladder contacture (1-22%),

incontinence,

impotence (nerve sparing available)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Treatment - localized disease - ADT -3

A

LHRH agonist +/- antiandrogen or orchiectomy,

goal serum testosterone <20ng/dl 1 mo after initiation of tx; &&&

ADT/XRT 62% vs 57% 10 yr OS vs XRT alone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Treatment - localized disease - dutasteride

A

in active surveillance pts, 38% vs 48% with placebo CA progression at 3 ys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

short term vs long term ADT

A

4-6 months versus 2-3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

androgen deprivation therapy -2

A

serum testosterone levels <50 ng/ml.

medical castration or surgical castration are equivalent.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Management of localized dz with low recurrence risk - NCCN -2 · T1-T2a · Gleason score <10 ng/mL
``` 10yr: #1 AS (· PSA at least as often as every 6 mo · DRE at least as often as every 12 mo · Repeat prostate biopsy as often as every 12 mo) ``` #2 RT or brachy #3 RP+/-PLND (IF: Lymph node metastasis: Observation or ADT or ADT + RT (category 2B), IF: Adverse features: RT or Observation) Adverse features: positive margins, seminal vesicle invasion, extracapsular extension, or detectable PSA
26
Management of localized dz with intermediate recurrence risk - NCCN -2 · T2b-T2c or · Gleason score 7 or · PSA 10-20 ng/mL
``` 10yr: #1 RT+/- short-term ADT, +/-brachytherapy or ``` #2 RP+/-PLND (IF: Lymph node metastasis: Observation or ADT or ADT + RT (category 2B), IF: Adverse features: RT or Observation) Adverse features: positive margins, seminal vesicle invasion, extracapsular extension, or detectable PSA
27
Management of localized dz with high recurrence risk - NCCN -2 · T3a or ·Gleason score 8-10 or · PSA >20 ng/mL
#1 RT+ long-term ADT (cat 1) #2 RT+brachytherapy+/- long-term ADT or #3 RP+/-PLND (IF: Lymph node metastasis: Observation or ADT or ADT + RT (category 2B), IF: Adverse features: RT or Observation)
28
Management of locally advanced (T3b-T4) OR localized dz with very high (not based on GS) recurrence risk - NCCN. -4pts T3b-T4 Gleason or PSA does not matter
#1 RT+ long-term ADT (cat 1) #2 RT+brachy+/- long-term ADT #3 RP+/-PLND (select pts, only if no fixation to adjacent organs, NOT COMMON) (IF: Lymph node metastasis: Observation or ADT or ADT + RT (category 2B), IF: Adverse features: RT or Observation) #4 ADT (select pts)
29
Management of N1 metastatic - NCCN
ADT or RT+ long-term ADT
30
Management of metastatic other than N1 - NCCN
ADT
31
Treatment - locally advance disease - XRT +/- neoadj/ adj /concurrent adt
std tx. improved OS, dz specific survival, and disease free survival. ADT drug choice does not change outcome.
32
Treatment - locally advance disease - RP
+/- neoadj/ adj /concurrent adt have shown no sig OS ->NOT recommended in combo with RP in this setting
33
Treatment - metastatic disease - general concepts
need to distinguish PSA recurrence vs overt mets. If PSA recurrence may start ADT if: PSA >50, rapid PSA velocity, long life expectancy--consider toxicity of ADT in pt. goal of ADT: palliation via elimination or inhibition of testosterone
34
Treatment - metastatic disease -orchiectomy -4
previous gold std (95% of testosterone pdt in testes), s/e: impotence, hot flashes; long term more likely to develop DM but NOT coronary heart dz, MI or sudden cardiac death like with LHRH a
35
Treatment - metastatic disease -LHRH agonists acute s/e -6
tumor flare, gynecomastia, hot flashes, ED, edema, inj site rxn
36
Treatment - metastatic disease -LHRH agonists long term s/e -6
osteoporosis, clinical fx, obesity, insulin resistance, alteration in lipids, inc risk of diabetes and CV events
37
hormonal regulation of prostate -4
hypothalamus->LHRH-> pituitary-> [[LH, FSH-> testes OR LH, FSH, PROL, GH->prostate cell OR ACH->adrenal gland]] -> [[testes->T OR adrenal gland->A]] -> T and A converted to DHT in prostate cell
38
LHRH agonist administration. -4
leuprolide depot (Lupron, Eligard) IM, goserelin (Zoladex) SQ; equal eff; decision made on cost and MD/pt dosing schedule preference
39
LHRH agonist tumor flare -4
initial induction of LH, FSH, inc bone pain or inc urinary sx, resolves in 2 weeks; antiandrogen should precede LHRH a and be continued in combo for at least 7 days in those with overt met dz
40
Intermittent androgen suppression
Con't until s &&&
41
Delayed versus immediate androgen suppression -4
2007 ASCO Guidelines – 3 different risk groups 1. Asym, PSA recurrence - no data 2. Progressive dz on watchful waiting - consider immediate though no OS benefit 3. Node (+) pts - consider immediate
42
Treatment - metastatic disease -second line hormonal. -6
1 Anti androgen withdrawal (moa unknown, Time of response depends on half-life differences, 6-8 wks for flutamide). 2 Corticosteroids (Suppress ACTH and subsequent A, pred 5-10qd). 3 aminoglutethimde. 4 ketoconazole (inh A synthesis, recommend corticosteroid replacement with hydrocortisone 20am,10pm) 5 megace 6 degarelix gnrh antagonist
43
CAB
Modest benefit, mixed studies, some consider as std
44
Intermittent androgen suppression
Con't until s &&&
45
Delayed versus immediate androgen suppression
2007 ASCO Guidelines – 3 different risk groups 1. Asym, PSA recurrence - no data 2. Progressive dz on watchful waiting - consider immediate though no OS benefit 3. Node (+) pts - consider immediate
46
Treatment - metastatic disease -second line hormonal -6
1 Anti androgen withdrawal (moa unknown, Time of response depends on half-life differences, 6-8 wks for flutamide). 2 Corticosteroids (Suppress ACTH and subsequent A, pred 5-10qd). 3 aminoglutethimde. 4 ketoconazole (inh A synthesis, recommend corticosteroid replacement with hydrocortisone 20am,10pm) 5 megace 6 degarelix gnrh antagonist
47
Degarelix -6
Gnrh antagonist, 2nd line. Major advantage speed in dropping testosterone levels. 7 days or less vs 28 days. Can be considered 1st line when tumor flare a concern. SQ inj. Has not been studied with CAB. S/e: inj site rxn, elevated lft's (10%)
48
Treatment - metastatic disease -antiandrogens -4
monotherapy with antiandrogens less effective the LHRH a, all equally similar efficacy in combo with LHRH a, more diarrhea with flutamide which is tid, less tox with bicalutamide which is daily
49
metatstatic castration resistant prostate CA - definition
serum T < 20 and disease progression
50
metatstatic castration resistant prostate CA - clinical benefit response. CBR -3
1. bone only dz difficult to assess by traditional response criteria 2. PSA decline only surrogate 3. analgesic consumption, pain scale rating, QOL
51
metatstatic castration resistant prostate CA - docetaxel 75mg/m2 q3wk + pred 5mg bid - first line -3
1st study to show OS inc. FDA approved. median survival 18.9mo. s/e: neutropenia 32%, FN 2.7%. studies combining with bev or lenalid do NOT improve OS, worse TOX
52
metatstatic castration resistant prostate CA - mitoxantrone 12mg/m2 + pred 5mg bid - typically second line
CBR 29% vs 12% with pred alone. Response duration 43 vs 18 weeks. No OS difference.
53
metatstatic castration resistant prostate CA - estramustine. -4
synthetic fusion of nitrogen mustard to estradiol. combined with vinblastine, etop, doce, and pac. with doce+dex inc median OS over mitox+pred but higher tox (NF, n/v, cardio events). meta-analysis shows inc OS but also inc thromboembolic events.
54
metatstatic castration resistant prostate CA - abiaterone dose and MOA. -3
empty stomach 1000mg daily+pred 5mg bid. blocks P450 CYP17, critical enzyme of T biosynthesis. pred blocks activation of cortisol deficit induced neg feedback mechanism.
55
metatstatic castration resistant prostate CA - abiaterone - first line. -3
median PFS 16.5 vs 8.83 mo with placebo. improved OS (# not yet known). inc time to chemo, need for opioids, PSA progression, and decline in PS
56
metatstatic castration resistant prostate CA - immunotherapy - sipuleucel-T - dose and MOA -2
give q2wks x3 doses. theraupeutic vax consisting of autologous peripheral blood mononuclear cells obtained through leukophoresis activated with PAP-GM-CSF.
57
metatstatic castration resistant prostate CA - immunotherapy - sipuleucel-T - trial -5
IMPACT trial. median OS 25.8 vs 21.7mo with placebo (p=0.03). consider for: 1. no or minimal sx 2. good PS 3. >6mo life expectancy 4. no visceral dz
58
metatstatic castration resistant prostate CA - second line. -7
abiaterone, cabazitaxel, mitoxantrone+pred, doce rechallenge, salvage chemo, sipuleucel-T, clinical trial
59
metatstatic castration resistant prostate CA - immunotherapy - abiaterone - second line outcome and ae -8
previous doce. median OS 14.8 vs 10.9 mo. improved time to PSA RR, PSA progression time, PFS. s/e: mineralocorticoid-related a/e of fluid retention, HTN hypokalemia muscle discomfort, hot flash, diarrhea, UTI
60
metatstatic castration resistant prostate CA - enzalutamide - dose and MOA -3
160mg daily. blocks androgen binding and translocation of A receptor into the nucleus and attachment to DNA. higher potency for A receptor than traditional antiandrogens.
61
metatstatic castration resistant prostate CA - enzalutamide
pg 818
62
Degarelix -6
Gnrh antagonist, 2nd line. Major advantage speed in dropping testosterone levels. 7 days or less vs 28 days. Can be considered 1st line when tumor flare a concern. SQ inj. Has not been studied with CAB. S/e: inj site rxn, elevated lft's (10%)
63
What defines recurrence risk?
tumor size, gleason score, PSA

BCOP (32 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions